Literature DB >> 28649135

Synthetic lethality and cancer.

Nigel J O'Neil1, Melanie L Bailey1, Philip Hieter1.   

Abstract

A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic interactions. Advances in next-generation sequencing technologies are enabling the identification of hundreds of tumour-specific mutations and alterations in gene expression that could be targeted by a synthetic lethality approach. The translation of synthetic lethality to therapy will be assisted by the synthesis of genetic interaction data from model organisms, tumour genomes and human cell lines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28649135     DOI: 10.1038/nrg.2017.47

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  122 in total

Review 1.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

Review 2.  High-throughput functional genomics using CRISPR-Cas9.

Authors:  Ophir Shalem; Neville E Sanjana; Feng Zhang
Journal:  Nat Rev Genet       Date:  2015-04-09       Impact factor: 53.242

3.  A robust toolkit for functional profiling of the yeast genome.

Authors:  Xuewen Pan; Daniel S Yuan; Dong Xiang; Xiaoling Wang; Sharon Sookhai-Mahadeo; Joel S Bader; Philip Hieter; Forrest Spencer; Jef D Boeke
Journal:  Mol Cell       Date:  2004-11-05       Impact factor: 17.970

4.  Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors.

Authors:  Yang Bian; Risa Kitagawa; Parmil K Bansal; Yo Fujii; Alexander Stepanov; Katsumi Kitagawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-14       Impact factor: 11.205

5.  Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae.

Authors:  A Bender; J R Pringle
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

6.  A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response.

Authors:  Britt Adamson; Thomas M Norman; Marco Jost; Min Y Cho; James K Nuñez; Yuwen Chen; Jacqueline E Villalta; Luke A Gilbert; Max A Horlbeck; Marco Y Hein; Ryan A Pak; Andrew N Gray; Carol A Gross; Atray Dixit; Oren Parnas; Aviv Regev; Jonathan S Weissman
Journal:  Cell       Date:  2016-12-15       Impact factor: 41.582

7.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Authors:  J Ross Chapman; Inger Brandsma; Guotai Xu; Jingsong Yuan; Martin Mistrik; Peter Bouwman; Jirina Bartkova; Ewa Gogola; Daniël Warmerdam; Marco Barazas; Janneke E Jaspers; Kenji Watanabe; Mark Pieterse; Ariena Kersbergen; Wendy Sol; Patrick H N Celie; Philip C Schouten; Bram van den Broek; Ahmed Salman; Marja Nieuwland; Iris de Rink; Jorma de Ronde; Kees Jalink; Simon J Boulton; Junjie Chen; Dik C van Gent; Jiri Bartek; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Nature       Date:  2015-03-23       Impact factor: 49.962

8.  Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Authors:  Louise J Barber; Shahneen Sandhu; Lina Chen; James Campbell; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; Daniel Nava Rodrigues; Jorge S Reis Filho; Victor Moreno; Joaquin Mateo; L Rhoda Molife; Johann De Bono; Stan Kaye; Christopher J Lord; Alan Ashworth
Journal:  J Pathol       Date:  2013-02       Impact factor: 7.996

9.  Pooled CRISPR screening with single-cell transcriptome readout.

Authors:  André F Rendeiro; Christian Schmidl; Paul Datlinger; Thomas Krausgruber; Peter Traxler; Johanna Klughammer; Linda C Schuster; Amelie Kuchler; Donat Alpar; Christoph Bock
Journal:  Nat Methods       Date:  2017-01-18       Impact factor: 28.547

10.  Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.

Authors:  Janessa Laskin; Steven Jones; Samuel Aparicio; Stephen Chia; Carolyn Ch'ng; Rebecca Deyell; Peter Eirew; Alexandra Fok; Karen Gelmon; Cheryl Ho; David Huntsman; Martin Jones; Katayoon Kasaian; Aly Karsan; Sreeja Leelakumari; Yvonne Li; Howard Lim; Yussanne Ma; Colin Mar; Monty Martin; Richard Moore; Andrew Mungall; Karen Mungall; Erin Pleasance; S Rod Rassekh; Daniel Renouf; Yaoqing Shen; Jacqueline Schein; Kasmintan Schrader; Sophie Sun; Anna Tinker; Eric Zhao; Stephen Yip; Marco A Marra
Journal:  Cold Spring Harb Mol Case Stud       Date:  2015-10
View more
  168 in total

1.  DNA Damage Repair Inhibitor for Breast Cancer Treatment.

Authors:  Ahrum Min; Kyung-Hun Lee; Seock-Ah Im
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Homeostatic plasticity fails at the intersection of autism-gene mutations and a novel class of common genetic modifiers.

Authors:  Özgür Genç; Joon-Yong An; Richard D Fetter; Yelena Kulik; Giulia Zunino; Stephan J Sanders; Graeme W Davis
Journal:  Elife       Date:  2020-07-01       Impact factor: 8.140

3.  Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.

Authors:  Akil Hamza; Leanne Amitzi; Lina Ma; Maureen R M Driessen; Nigel J O'Neil; Philip Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 4.  Polyamine synthesis as a target of MYC oncogenes.

Authors:  André S Bachmann; Dirk Geerts
Journal:  J Biol Chem       Date:  2018-11-07       Impact factor: 5.157

5.  Disrupting a negative feedback loop drives endocrine therapy-resistant breast cancer.

Authors:  Charles E Foulds
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-06       Impact factor: 11.205

Review 6.  Genetic interaction networks in cancer cells.

Authors:  Barbara Mair; Jason Moffat; Charles Boone; Brenda J Andrews
Journal:  Curr Opin Genet Dev       Date:  2019-04-08       Impact factor: 5.578

7.  The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer.

Authors:  Chi-Wen Luo; Ming-Feng Hou; Chia-Wei Huang; Chun-Chieh Wu; Fu Ou-Yang; Qiao-Lin Li; Cheng-Che Wu; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 8.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

9.  Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.

Authors:  Liam Baird; Takafumi Suzuki; Yushi Takahashi; Eiji Hishinuma; Daisuke Saigusa; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-10-26       Impact factor: 4.272

10.  Enzymatic Self-Assembly Confers Exceptionally Strong Synergism with NF-κB Targeting for Selective Necroptosis of Cancer Cells.

Authors:  Jie Zhou; Xuewen Du; Xiaoyi Chen; Jiaqing Wang; Ning Zhou; Difei Wu; Bing Xu
Journal:  J Am Chem Soc       Date:  2018-02-06       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.